Mcpip protection against osteoclast production
AssigneeUniversity of Central Florida Research Foundation, Inc.
InventorPappachan Kolattukudy
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating a patient at risk of developing an inflammatory joint disease. In exemplary embodiments, the method involves inhibiting MCPIP levels in a patient in need, wherein said patient in need is exhibiting pre-arthritic or pre-osteoporotic symptoms.
Claims22
A method of treating a condition in a patient in need, the method comprising administering to the patient a therapeutically effective amount of a composition that inhibits the expression or action of MCPIP, wherein said condition comprises abnormal osteoclast-induced bone resorption.
A method of inhibiting osteoclast production in a patient in need, comprising:
- administering a therapeutically effective amount of a composition that inhibits the expression or action of MCPIP in the patient.
A method of treating an inflammatory disease in a patient in need thereof, said method comprising:
- procuring human bone marrow mononuclear cells (BMCs) from said patient to obtain procured BMC's;
- treating said procured BMC's, ex vivo, by blocking expression of MCPIP in said cells to obtain treated BMC's;
- administering said treated BMC's to said patient.
Dependencies are inferred from the claim text.